Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy.

Area of Science:

• Cardiology
• Critical Care Medicine
• Sepsis Pathophysiology

Background:

• Sepsis-induced cardiomyopathy lacks a universally accepted definition, leading to significant heterogeneity in research data.
• Inconsistent definitions complicate the interpretation of incidence, prognosis, and clinical significance of sepsis-induced cardiomyopathy.
• Emerging diagnostic technologies, while informative, have further complicated the definition and understanding of this condition.

Purpose of the Study:

• To explore the definitions of sepsis-induced cardiomyopathy.
• To analyze how varying definitions impact data interpretation.
• To discuss long-term prognosis and management considerations for sepsis-induced cardiomyopathy.

Main Methods:

• Review of existing literature on sepsis-induced cardiomyopathy definitions.
• Analysis of clinical trial data and meta-analyses.
• Evaluation of diagnostic techniques and their impact on understanding pathophysiology.

Main Results:

• Lack of consensus on definition hampers consistent interpretation of sepsis-induced cardiomyopathy data.
• Heterogeneity in studies leads to disparities in estimated incidence, prognosis, and clinical significance.
• Limited evidence suggests unique treatment for sepsis-induced cardiomyopathy beyond standard heart failure management, though reversibility is noted.

Conclusions:

• Clear definitions are essential for accurate interpretation of sepsis-induced cardiomyopathy data and prognosis.
• Guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) is a logical approach for persistent cardiac dysfunction post-sepsis.
• Clinicians should focus on key cardiac function parameters to tailor and adjust therapeutic strategies based on patient response.